High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide…

Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma.

Study published by Dr. S. Vincent Rajkumar in The Lancet Oncology, 10/22/09

Read more on the Mayo Clinic News blog.

Tags: dexamethasone, Hematology, oncology